Clinical trials: Treatment Resistant Depressive Disorder
Treatment Resistant Depression, Inflammation
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not responded well to standard…
- Conditions
- Treatment Resistant Depression, Inflammation, Overweight
- Trial name
- NCT05774665
- Testing
- Omega 3
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Treatment-Resistant
Biomarkers of Theta Burst Stimulation in Major Depressive Disorder
This study investigates the brain-based biomarkers of treatment response to accelerated theta burst stimulation (aTBS) in patients with Major Depressive Disorder resistant to pharmacological treatment(MDD) in an open label design.
- Trial name
- NCT03626181
- Testing
- Theta Burst Stimulation ( Transcranial Magnetic Stimulation)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of Calgary
Treatment Resistant Depression
Virtual Neuro-Navigation System for Personalized Community Based TMS
Phase I study of a virtual neuro-navigation package with built-in support for identifying specific "surface-based" targets to optimze TMS treatment.
- Trial name
- NCT04956081
- Testing
- Neuro-navigated Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Soterix Medical
Treatment Resistant Depression
Accelerated High-dose Sequential Bilateral Theta Burst Stimulation for Treatment Resistant Depression
Repetitive transcranial magnetic stimulation (rTMS) and Theta burst stimulation (TBS) are approved by the US. Food and Drug administration (FDA) for the treatment of refractory major depression.
- Trial name
- NCT05811104
- Testing
- Sequential bilateral theta burst stimulation
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Treatment Resistant Depression
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
The primary objective of this study is to assess short, mid and long-term clinical outcomes in patients with difficult to treat depression (such as patients with treatment resistant depression) treated with Vagus Nerve…
- Trial name
- RESTORE-LIFE (NCT03320304)
- Testing
- Vagal Nerve Simulation (VNS) Therapy
- Where
- 18 sites in Austria, Belgium and 2 more
- Volunteers
- 500 people
- Sponsor
- LivaNova
Major Depressive Disorder, Treatment Resistant Depression
Antidepressant Effects of Nitrous Oxide
To evaluate the acute and sustained antidepressant effects of nitrous oxide in people with major depressive disorder; and further evaluate these effects by identifying the optimal dose and regimen to guide current practice, and…
- Trial name
- NCT05357040
- Testing
- Nitrous oxide gas for inhalation
- Where
- 2 sites in United States, Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Chicago
Depressive Disorder, Treatment-Resistant
Lithium Versus Quetiapine in Treatment Resistant Depression
LQD is a multicentre randomised clinical trial comparing the clinical and cost effectiveness of lithium versus quetiapine when used as add-on therapies to antidepressant medication for patients with treatment resistant…
- Trial name
- LQD (NCT03004521)
- Testing
- Quetiapine, Lithium
- Where
- United Kingdom
- Volunteers
- 276 people
- Sponsor
- King's College London
Treatment Resistant Depression, Major Depressive Disorder
Stellate Ganglion Block for Major Depressive Disorder.
This is a feasibility study, to investigate a new treatment option for major depressive disorders by performing a Stellate Ganglion Block (SGB).
- Trial name
- NCT04727229
- Testing
- Bupivacaine Hydrochloride, Normal Saline
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Unity Health Toronto
Treatment-resistant Depression
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
The study aims to investigate the safety and efficacy of oral psilocybin administered under supportive conditions in treatment-resistant major depression (TRD).
- Trial name
- EPIsoDE (NCT04670081)
- Testing
- Psilocybin, Nicotinamide
- Where
- 2 sites in Germany
- Volunteers
- 144 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Late-Life Depression, Resistant Depression, Treatment
Nitrous Oxide for Late-Life Depression - PROTO-BRAIN
Resistant Depression is a common condition in older adults and there is an urgent need for novel antidepressant in this population.
- Trial name
- PROTO-BRAIN (NCT05007028)
- Testing
- EMONO, Medical Air
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Tours
Major Depressive Disorder
Deep rTMS for Treatment-Resistant Late-life Depression
In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 who have been unable to tolerate or failed to respond…
- Trial name
- rTMS (NCT01860157)
- Testing
- Brainsway H1-Coil Deep TMS System
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depression
Evaluation of the Deep TMS H-Coil in the Treatment of Major Depression- Augmentation of Antidepressant Medication
Evaluation of the novel deep TMS H-Coil design as an augmentation measure in the treatment of medication resistant major depression. Stimulation is administered with and without cognitive-emotional provocation.
- Trial name
- NCT00460902
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- 2 sites in Israel
- Volunteers
- 57 people
- Sponsor
- Hadassah Medical Organization
Treatment-resistant Depression
Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression
About one-third of depressed patients will not get better after multiple antidepressant treatments. This situation put a high burden on patients with depression due to worsening quality of life and increasing health care costs.
- Trial name
- NCT02360280
- Testing
- ketamine, midazolam
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- VA Office of Research and Development
Treatment Resistant Depression, Autism Spectrum Disorder
Psilocybin for Treatment-Resistant Depression in Autism
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD).
- Trial name
- PAT-DA (NCT06731621)
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Centre for Addiction and Mental Health
Depressive Disorder
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression
This Phase 2a pilot, exploratory, randomized, double-blind, placebo-controlled, parallel-group trial will estimate whether concurrent fluoxetine alters the antidepressant effect, acute psychedelic experience, or safety of a…
- Trial name
- COGUNILA (NCT06898606)
- Testing
- Psilocybin and Psilocyn, Psychotherapy-assisted session, Fluoxetine
- Where
- Brazil
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Federal University of Latin American Integration
Treatment-resistant Depression (TRD)
Auditory MMN EEG in TRD in Response to Ketamine
To develop and test a neurocomputational model of ketamine treatment response predictions in TRD.
- Trial name
- NCT05464264
- Testing
- Ketamine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Subjects Had Unipolar, Non-psychotic Major Depression
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression
Atypical neuroleptics may have antidepressant qualities in bipolar depression and in unipolar depression. Some data support the use of both Risperidone and Olanzapine, but there are no direct comparisons of their relative…
- Trial name
- NCT01282632
- Testing
- Risperidone, Olanzapine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment Resistant Depression
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
This study will evaluate the efficacy and safety of NV-5138 in adults with TRD
- Trial name
- NCT05066672
- Testing
- NV-5138
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Navitor Pharmaceuticals, Inc.
Major Depressive Disorder
Deep Brain Stimulation for Treatment Resistant Depression
The purpose of this study is to test the safety, efficacy and mechanism of action of subgenual cingulate (Cg25) deep brain stimulation (DBS) for major depression in patients who have not responded to prior antidepressant…
- Trial name
- NCT00367003
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Emory University